The pharmacokinetics of gefitinib in a Chinese cancer population group: a virtual clinical trials population study
H Yu, RKS Badhan - Journal of Pharmaceutical Sciences, 2021 - Elsevier
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The pharmacokinetics of gefitinib in a Chinese Cancer population group: a virtual clinical trials population study
H Yu, RKS Badhan - Journal of Pharmaceutical Sciences, 2021 - research.aston.ac.uk
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The pharmacokinetics of gefitinib in a Chinese cancer population group: a virtual clinical trials population study.
H Yu, RK Singh Badhan - 2021 - cabidigitallibrary.org
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study
H Yu, RKS Badhan - Journal of pharmaceutical sciences, 2021 - pubmed.ncbi.nlm.nih.gov
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study.
H Yu, SB RK - Journal of Pharmaceutical Sciences, 2021 - europepmc.org
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study
H Yu, RKS Badhan - Journal of Pharmaceutical Sciences, 2021 - jpharmsci.org
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study
H Yu, RKS Badhan - Journal of Pharmaceutical Sciences, 2021 - jpharmsci.org
Gefitinib, a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase,
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …
is used to treat non-small-cell lung cancer (NSCLC). Lung cancer rates are high in China …